Merck’s Keytruda + Padcev Received the US FDA Approval for the Treatment of Urothelial Cancer
Shots:
- The approval was based on the P-III (KEYNOTE-A39) trial evaluating Keytruda + Padcev vs CT (gemcitabine + cisplatin/carboplatin) in patients (n=886) with locally advanced or metastatic urothelial cancer. The result of the study demonstrated statistically significant improvement in OS & PFS
- Additionally, the result also demonstrated a median OS of 31.5 vs 16.1mos. along with a reduced risk of death by 53% & disease progression by 55%. Median PFS was 12.5 vs 6.3mos. & ORR was 68% vs 44%. Furthermore, CR was found to be 29% vs 12%, & PR was 39% vs 32%
- Keytruda, humanized mAb activates T lymphocytes, which may have an impact on both tumor cells and healthy cells, by interfering with the interaction between PD-1 and its ligands, PD-L1 and PD-L2
Ref: Merck | Image: Merck
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
